Objective: Non-invasive prenatal detection of aneuploidies can be achieved with high accuracy through sequencing of cell-free maternal plasma DNA in the maternal blood plasma.
| INTRODUCTION
The discovery of cell-free DNA (cfDNA) of placental origin in the maternal circulation in 1997 4 and the demonstration that fetal aneuploidies can readily be identified by cell-free maternal plasma DNA analysis, 5, 6 triggered swift clinical implementation of non-invasive prenatal testing (NIPT). NIPT allows the early detection of trisomy 13, 18 , and 21 via blood sampling, avoiding the significant risk of invasive procedure-induced miscarriage. 7 Genome-wide random and targeted massively parallel sequencing 6, [8] [9] [10] [11] are the 2 main approaches applied for the detection of common fetal aneuploidies. Both approaches show high sensitivity and specificity for detection of fetal trisomy 21, 18, and 13. [12] [13] [14] In fact, a recent bivariate meta-analysis on the performance of cfDNA screening for trisomy 21 demonstrated an overall sensitivity and specificity of 99.4% and 99.9%, respectively. 15 Because of this high accuracy, professional medical organizations propose that NIPT can replace conventional screening methods for common aneuploidies across the maternal age spectrum when accompanied by pre-test counselling. 3, 16 However, a small number of false positive and false negative NIPT results remain.
It has been demonstrated that the presence of (1) a (vanishing) twin, (2) maternal copy number variants (CNVs) as small as 500 kb, or (3) the occurrence of undiagnosed cancer in pregnant women influences the genomic representation profiles (GR-profiles) and can skew the overall Z-scores which in turn may lead to erroneous fetal aneuploidy estimates. 2, [17] [18] [19] [20] Independent lines of evidence derived from confirmatory amniocentesis or follow-up studies analyzing the cytotrophoblast suggest however that the main cause for biological false positive NIPT results is the occurrence of fetoplacental mosaicism. 1, 21 Confined placental mosaicism (CPM), in which the abnormal cell line occurs almost solely in the placenta and not in amniotic cells or other fetal tissue, has been reported to occur in 1% to 2% of pregnancies during the first trimester. 22, 23 The presence of aneuploid placental cell lineages can affect the placental function. In particular, 16% to 21% of pregnancies with CPM show prenatal complications. 22, 24, 25 Recently, Pertile et al show the association of rare autosomal trisomies (RATs) detected by NIPT with miscarriages, true fetal mosaicism, intrauterine growth retardation (IUGR), intrauterine fetal death, and confirmed or suspected uniparental disomy. 26 In the current study, we implement a novel analytical approach which detects the presence and estimates the degree of (C)PM. The novel analysis pipeline was applied retrospectively to almost 20 000 sequenced cfDNA samples. We demonstrate that the presence of fetoplacental mosaicism is accurately predicted in 90% of the cases.
In addition, the method can identify discordant chromosomal constitution in twin pregnancies. This additional information has important clinical implications which can guide genetic counselling, invasive testing, pregnancy monitoring, and ultrasound examinations resulting in a better overall pregnancy management. to account for the fact that the fetus contributes 50% extra alleles (3 instead of 2) of the chromosome of interest to the circulating cfDNA. In Figure 1 and Suppl. Figure 1 and Figure 2 , the full diagonal line corresponds to the expected read count Mean.
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What is already known about this topic?
• Non-invasive prenatal detection of fetal aneuploidies can be achieved with high accuracy through sequencing of circulating cell-free DNA (cfDNA) in maternal plasma.
• Current sequencing-based bioinformatics pipelines report common trisomies [1] [2] [3] ignoring the status of other autosomal chromosomes and do not predict the presence of mosaicism
What does this study add?
• The presented aneuploidy detection pipeline, combined with fetal fraction determination, permits the noninvasive detection of aneuploidies in all chromosomes and pinpoints cases at high risk for fetoplacental mosaicism.
• Reporting about the presence of mosaicism in the placenta can influence risk estimation of a possible miscarriage, aid in the prenatal management, and improve genetic counseling in future pregnancies.
Deviations from this linear prediction can be attributed partly to variations in the measurement of both ChromRC and FF, partly to the possibility that the fetus does not contribute exactly 50% extra alleles, for instance due to CPM. Ideally, the measurement variation should be estimated from cases with known degrees of mosaicism ranging between 0% and 100%. In practice, however, such precise data are only available for normal cases, where the degree of mosaicism is assumed to be exactly 0%. In Figure 1 , the standard deviation SD.ChromRC.normal calculated from these normal cases is used to mark a ±3*SD.ChromRC. Cases with a Z > 3 and TriZ < −3 are labelled as TriZ-low (Table 2A,B) . These represent cases where the observed ChromRC 
| Confirmatory invasive testing
When cfDNA profiling indicated the presence of a chromosomal abnormality, the women were offered follow-up by standard invasive prenatal diagnosis based on DNA extracted from chorionic villus sampling (CVS) or amniotic fluid (AF). Subsequently, when a discrepancy between the NIPT and the invasive genetic test result was detected, women were proposed to donate the placenta upon delivery. To this end, upon their informed consent, the women were provided with a sampling vial which they presented to the midwife upon delivery.
Chromosome microarray analysis was performed on DNA extracted from CVS or AF as described in Brady et al (2015) , 28 be present in the fetus (ie, detected in AF; Table 2B ). All but 1 of the chromosome 2, 7, 8, 16, and 20 RATs were confined to the placenta, with a different degree of placental mosaicism depending on the region sampled (Table 2B) In 12 cases, only AF was sampled, and no mosaicism was detected.
These results may indicate false positives. More likely, they may represent CPM, because placenta was not investigated. In 2 cases, both AF and CVS samples did not show evidence of the predicted mosaicism.
Whereas these might indeed indicate false positives, we cannot exclude the possibility that the tested regions of the placenta do not represent the whole placenta. For the remaining cases, no placental material could be obtained to further test for the presence of CPM (Table 2A ). In conclusion, in 20/22 or 90% of cases where a placental mosaicism was detected, the mosaicism was confirmed upon sampling the placenta. UPD testing was performed in 12 cases (7, 2, 1, and 2
cases of trisomy 7, 11, 15, and 16, respectively). Only in 1 pregnancy, the fetus showed a mosaic trisomy with UPD for chromosome 15. This case was previously reported in Bayindir et al (2015) . 18 In twin pregnancies, 1 twin can have a trisomy whereas the other twin can be normal. Hence, the algorithm presented should allow to predict the presence of a chromosomal aneuploidy in one of the placentas of either twin. Indeed, this was observed in 2 pregnancies, 1 trisomy 13, and another with a trisomy 21 (arrows in Figure 1 ).
| Predicted non-mosaic trisomies can be mosaic
The In addition, due to the presence of differences in the degree of mosaicism in placenta and fetus, a fetal mosaicism may not be identified if the placenta is not mosaic. For the common trisomies (13, 18, and 21) , the prediction of non-mosaic trisomies was confirmed in all fetuses and/or placentas (Table 1A ) except for 3 cases that proved to be fetal mosaic aneuploidies. For the RATs, 4 out of 20 predicted predicted non-mosaic trisomies were proven mosaic upon invasive testing (Table 1A) . Among these, 1 pregnancy with a predicted trisomy 15 was terminated at 23 weeks of gestation due to anhydramnion.
For this case, arrayCGH, FISH, and molecular analysis on fetal blood showed a normal result with the absence of UPD15. Another case with a trisomy 22 was normal upon AF analysis (arrayCGH and FISH analysis), whereas follow-up FISH of 3 placental biopsies confirmed the presence of trisomy 22 in 75% to 80% and~37% of the cells, respectively.
| DISCUSSION
We developed and implemented a method to identify samples with a high likelihood of placental chromosomal mosaicism. The sensitivity of the method to predict placental mosaicism increases with increasing FF. When a mosaicism was predicted by the algorithm, the placental mosaicism was confirmed in approximately 90% (20/22) cases where the placenta was sampled. In the remaining cases, no aneuploidy was detected in the analyzed placental biopsies, which does not exclude the presence of an aneuploidy cell line elsewhere in the placenta.
Overall, this analysis provides a unique view on the incidence of mosaic chromosomal aneuploidies in trisomic fetuses and placentas.
The proportion of mosaicism for the common aneuploidies trisomy 21, 18, and 13 was 3.2% (5/154), 12.8% (5/39), and 13.3% (2/15), respectively (Table 2A) . These numbers are slightly higher than previously reported by Konialis and Pangalos (2015) . 30 In their large study of 73 268 fetal conventional karyotypes, trisomy 21, 18, and 13 mosaicism was detected in 2%, 4.8%, and 9.6%, respectively. The case with tetrasomy/trisomy mosaicism has been reported. 34 The ability to identify pregnancies with chromosomal fetoplacental mosaicisms and the ability to estimate the degree of placental mosaicism can improve clinical guidance of the pregnancy.
CPM was first described by Kalousek and Dill 22 in term placentas of infants born with unexplained IUGR. It has been estimated that 16%
to 21% of pregnancies with CPM show prenatal or perinatal complications. 22 The detection of RATs, which are often CPMs, has been in patients with birth defects. 35 However, for RATs, the mosaicism is most often confined to the placenta. If a chromosomal aneuploidy is restricted to the placenta, NIPT analysis would suggest the presence of an aneuploidy whereas the genetic analysis of the fetus is normal.
To test this hypothesis, we sampled placentas from 14 pregnant women where the NIPT and invasive genetic testing results were conflicting. In 9 of these, we demonstrated that the positive NIPT result was indeed the consequence of placental mosaicism. CPM was especially pronounced in the RATs (Figure 3 ).
Another value of detecting chromosomal mosaicism is that they can be indicators for increased risk for fetal UPD. 36 UPD in humans is caused primarily by meiotic nondisjunction events, followed by trisomy or monosomy "rescue." Not surprisingly, the incidence of UPD increases with maternal age. UPDs were initially detected as mosaic trisomies during routine prenatal diagnosis by CVS or amniocentesis. 37 Now, we are capable of detecting some mosaic trisomies non-invasively. The risk for (fetal) developmental disorders is the highest for chromosomes known to carry imprinted genes. The most severe developmental disorders are UPD7 (Silver-Russel Syndrome), UPD14, and UPD15 (Prader-Willi/Angelman Syndrome).
When NIPT indicated the presence of (mosaic) trisomy but invasive testing was normal, UPD testing was performed. Only in 1 pregnancy, the fetus proved to be a mosaic trisomy and UPD for chromosome 15.
This case was earlier reported in Bayindir et al (2015) . 18 In a published analysis of 16 885 pregnancies, 7 RATs were shown to have resulted in a UPD cell line in the fetus 26 The consequence of the apparent random distribution of chromosomal changes is that the method can never exclude the presence of an aneuploidy restricted to the fetus or, conversely, a non-mosaic trisomy in the placenta with a normal diploid fetus. In addition, cfDNA is derived from the cytotrophoblast whereas placental biopsies can contain both cytotrophoblasts as well as the mesenchymal core cells. 38 Discrepancies between the genetic constitution of the different cell layers of the placenta, trisomy or monosomy confined to the cytotrophoblast or mesenchyme, have been well described in the literature. 39 Despite all potential advantages, it remains controversial whether genome-wide NIPT analysis should be implemented in the routine clinical setting. The main concern is a potential increase in the number of invasive procedures to follow-up (false) positive results which can be either biological (a consequence of CPM) or technical in origin. As shown here, many of the RATs are indeed confined to the placenta. However, we believe this information can improve pregnancy management. It should be noted that aneuploidy detection does not necessarily need to result in invasive testing but may rather lead to expert ultrasound follow-up. Subsequently, results of both the genetic testing and fetal ultrasound can be disclosed to the pregnant women.
In our experience, after discussing the low risk for developmental following an abnormal NIPT result should be informed that the tissue being sampled is not of fetal origin and that mosaic conditions can also occur.
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